References
- Nordt SP, Williams SR, Turchen S. Manoguerra A, Smith D, Clark RF. Hypermagnesemia following an acute ingestion of Epsom salt in a patient with normal renal function. J Toxicol Clin Toxicol 1996; 34: 735–9.
- Campbell WA. Oxalic acid, Epsom salt and the poison bottle. Hum Toxicol 1982; 1: 187–93.
- Ditzler JW. Epsom-salt poisoning and a review of magnesium-ion physiology. Anesthesiology 1970; 32: 378–80.
- Rees PO. A case of poisoning by Epsom salt. J Forensic Sci Soc 1970; 10: 91–4.
- Birrer RB, Shallash AL Totten V. Hypermagnesemia-induced fatality following Epsom salt gargles. J Emerg Med 2002; 22: 185–8.
- Fawcett WJ, Haxby EJ, Male DA. Magnesium: phy-siology and pharmacology. Br J Anaesth 1999; 83: 302–20.
- Hasenfuss G, Pieske B, Casten M, et al. Influence of the novel inotropic agent levosimendan on isometic tension and calcium cycling in failing human myo-cardium. Circulation 1998; 98: 2141–7.
- Slawsky MP, Colucci WS, Gottlieb SS, et al. Acute haemodynamic and clinical effects of levosimendan in patients with severe heart failure. Circulation 2000; 102: 2222–7.
- Kivikko M, Lehtonen L, Colucci WS, et al. Sustained haemodynamic effects of intravenous levosimendan. Circulation 2003; 107: 81–6.
- Follath F, Cleland JG, Just H, et al. Efficacy and safety of intravenous levosimendan compared with dobuta-mine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 2002; 360: 196–202.
- Moiseyev VS, Poder P. Andrejevs N, et al. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomised, placebo-con-trolled, double-blind study (RUSSLAN). Euro Heart J 2002; 23: 1422–32.
- Bach PB, Schrag D, Nierman DM, et al. Identification of poor prognostic features among patients requiring mechanical ventilation after hematopoietic stem cell transplantation. Blood 2001; 98: 3234–40.
- Massion PB, Dive AM, Doyen C, et al. Prognosis of hematologic malignancies does not predict intensive care unit mortality. Crit Care Med 2002; 30: 2260–70.
- Faber-Langendoen K, Caplan AL, McGlave PB. Survi-val of adult bone marrow transplant patients receiving mechanical ventilation: a case for restricted use. Bone Marrow Transplant 1993; 12: 501–7.
- Price KJ, Thall PF, Kish SK, Shannon VR, Andersson BS. Prognostic indicators for blood and marrow transplant patients admitted to an intensive care unit. Am J Respir & Crit Care Med 1998; 158: 876–84.
- Huaringa AJ, Leyva FJ, Giralt SA, et al. Outcome of bone marrow transplantation patients requiring me-chanical ventilation (comment). Crit Care Med 2000; 28: 1014–17.
- Afessa B, Tefferi A, Dunn VVF, Litzow MR, Peters SG. Intensive care unit support and Acute Physiology and Chronic Health Evaluation III performance in hema-topoietic stem cell transplant recipients. Crit Care Med 2003; 31: 1715–21.
- Benoit D, Vandewoude K, Decruyenaere J, Hoste E, Colardyn F. Outcome and early prognostic indicators in patients with a haematological malignancy ad-mitted to the intensive care unit for a life-threatening complication. Crit Care Med 2003; 31: 104–12.
- Khassawneh BY, White P Jr, Anaissie EJ, Barlogie B, Hiller FC. Outcome from mechanical ventilation after autologous peripheral blood stem cell transplantation. Chest 2002; 121: 185–8.
- Rubenfeld G, Crawford S. Withdrawing life support from mechanically ventilated recipients of bone-marrow transplants. Ann Int Med 1996; 125: 625–33.
- Groeger J, Bach P. Consider saying yes. Crit Care Med 2003; 31: 320–1.
- Crawford SW, Schwartz DA, Petersen FB, Clark JG. Mechanical ventilation after marrow transplantation. Risk factors and clinical outcome. Am Rev Respir Dis 1988; 137: 682–7.